(2020) COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurology-Neuroimmunology & Neuroinflammation. ISSN 2332-7812
Full text not available from this repository.
Abstract
In December 2019, a novel coronavirus causing an infectious respiratory disease (COVID-19) was identified, which since then has developed into a pandemic with higher rates of mortality in older individuals and those with underlying medical conditions. 1 Multiple sclerosis (MS) is an immune-mediated neurologic disease which requires long-term treatment with immuno- therapies that have been shown to increase the risk of infections.2 As a result, there is significant anxiety among patients and neurologists during the pandemic regarding the infection outcome in this patient population. We present a patient with MS treated with fingolimod who was diagnosed with COVID-19 and had a favorable outcome.
| Item Type: | Article |
|---|---|
| Keywords: | COVID-19, multiple sclerosis |
| Subjects: | WC Communicable Diseases > WC 500-590 Virus Diseases WL Nervous System |
| Divisions: | Faculty of Medicine > Departments of Clinical Sciences > Department of Neurology Isfahan Neurosciences Research Center |
| Journal or Publication Title: | Neurology-Neuroimmunology & Neuroinflammation |
| Journal Index: | ISI |
| Volume: | 7 |
| Number: | 4 |
| Identification Number: | https://doi.org/10.1212/NXI.0000000000000753 |
| ISSN: | 2332-7812 |
| Depositing User: | Zahra Otroj |
| URI: | http://eprints.mui.ac.ir/id/eprint/12301 |
Actions (login required)
 |
View Item |